Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Value of a Tailored-based, Exercise Program for Improving Quality of Life of Patients With Hematologic Malignancies: a Pilot Randomized Trial

NCT07912684 is registered in ClinicalTrials.gov with Gruppo Italiano Malattie EMatologiche dell'Adulto as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07912684 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
The Value of a Tailored-based, Exercise Program for Improving Quality of Life of Patients With Hematologic Malignancies: a Pilot Randomized Trial
Lead sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase
Not applicable
Overall status
Recruiting
Start date
November 10, 2026
Completion date
November 10, 2028
Enrollment
75 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, lymphoma, multiple myeloma

Arms

As registered; 2 arms.

  • Structured Exercise Program (SEP) ExperimentalStructured Exercise Program (SEP)

    Participants randomized to the intervention group will receive a 16-week personalized, supervised, hybrid structured exercise program (SEP), combining home- and gym-based training. The program includes aerobic, resistance, balance, and stretching exercises, a structured walking program, and behavioral counseling. Exercise sessions will be supervised by trained exercise professionals, either in person or remotely, according to the intervention phase.

  • Control No intervention

    Participants randomized to the control group will receive usual care and general information about the benefits of physical activity. They will not participate in the supervised structured exercise program during the study period.

Primary endpoints

Registered primary outcome measures; 2 primary.

  • Adherence to the Structured Exercise Program At 16 weeks (end of intervention)

    Adherence will be assessed as the percentage of participants in the intervention group who attend at least 65% of the planned supervised exercise sessions. The intervention will be considered feasible if at least 70% of participants meet this adherence t

  • Patient Satisfaction With the Structured Exercise Program At 16 weeks (end of intervention)

    Patient satisfaction will be assessed in the intervention group using the item "Overall, I am satisfied with the exercise program" from a study-specific satisfaction questionnaire. Responses are rated on a 4-point scale: "disagree", "somewhat disagree", "somewhat agree", and "agree". Satisfaction will be measured as the percentage of participants responding "somewhat agree" or "agree". The intervention will be considered feasible if at least 75% of participants meet this satisfaction criterion.

Lead sponsor's other trials

Gruppo Italiano Malattie EMatologiche dell'Adulto, most recent start first.

Similar trials

Same condition (Multiple Myeloma) and phase, most recent start first.